Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) Receives Average Recommendation of “Hold” from Analysts

Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) has been given an average recommendation of “Hold” by the five ratings firms that are covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, two have assigned a hold recommendation, one has issued a buy recommendation and one has issued a strong buy recommendation on the company. The average twelve-month target price among brokers that have issued ratings on the stock in the last year is $40.00.

SNSE has been the subject of a number of research analyst reports. Wall Street Zen raised Sensei Biotherapeutics to a “hold” rating in a report on Saturday, December 27th. Leerink Partners initiated coverage on Sensei Biotherapeutics in a report on Monday. They issued an “outperform” rating and a $50.00 target price for the company. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Sensei Biotherapeutics in a report on Monday, December 29th. Finally, Zacks Research raised Sensei Biotherapeutics to a “hold” rating in a report on Tuesday.

Hedge Funds Weigh In On Sensei Biotherapeutics

A hedge fund recently raised its stake in Sensei Biotherapeutics stock. Renaissance Technologies LLC raised its stake in Sensei Biotherapeutics, Inc. (NASDAQ:SNSE) by 10.6% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The fund owned 11,516 shares of the company’s stock after buying an additional 1,100 shares during the period. Renaissance Technologies LLC owned about 0.91% of Sensei Biotherapeutics worth $123,000 as of its most recent SEC filing. 10.50% of the stock is owned by institutional investors and hedge funds.

Sensei Biotherapeutics Stock Performance

Sensei Biotherapeutics stock opened at $31.64 on Thursday. Sensei Biotherapeutics has a 52 week low of $5.25 and a 52 week high of $36.76. The stock has a market capitalization of $42.40 million, a P/E ratio of -1.90 and a beta of -0.10. The stock has a fifty day moving average of $28.78 and a 200-day moving average of $16.43.

Sensei Biotherapeutics (NASDAQ:SNSE) last posted its quarterly earnings results on Monday, March 30th. The company reported ($3.74) EPS for the quarter, topping analysts’ consensus estimates of ($4.81) by $1.07. On average, research analysts forecast that Sensei Biotherapeutics will post -2.77 earnings per share for the current year.

About Sensei Biotherapeutics

Sensei Biotherapeutics, Inc is a clinical-stage biotechnology company focused on the discovery and development of immunotherapies that harness both the innate and adaptive arms of the immune system to treat cancer and autoimmune diseases. Utilizing proprietary antibody engineering and biologics platforms, Sensei aims to develop next-generation checkpoint modulators and immune agonists designed to overcome the limitations of current therapies.

The company’s lead programs include SIS-100, a first-in-class antagonist targeting Siglec-15 being evaluated in solid tumors to relieve immune suppression in the tumor microenvironment, and SIS-101, an antibody directed against CD39 intended to restore T-cell function by modulating adenosine signaling pathways.